Trial Profile
Partial neuromuscular blockade to facilitate lung and diaphragm protective mechanical ventilation in ICU patients. A randomized controlled pilot study.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Rocuronium bromide (Primary)
- Indications Muscle hypertonia; Neuromuscular blockade
- Focus Adverse reactions; Therapeutic Use
- 19 May 2020 Planned End Date changed from 30 Mar 2019 to 31 Dec 2020.
- 19 May 2020 Planned primary completion date changed from 30 Mar 2019 to 31 Dec 2020.
- 02 Nov 2018 Status changed from not yet recruiting to recruiting.